| Description | Azithromycin is a macrolide antibiotic useful for the treatment of a number of bacterial infections. |
|---|
| Related Catalog | Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Anti-infection >> Bacterial Research Areas >> Infection |
|---|
| In Vitro | Azithromycin (2 μM) augments rhinovirus-induced IFNβ expression in primary bronchial epithelial cells from asthmatics, which is associated with over-expression of RIG-I like receptors and repression of viral replication. Knockdown of MDA5, but not knockdown of RIG-I, diminishes azithromycin (2 μM)-enhanced viral-induced IFNβ expression in asthmatic primary bronchial epithelial cells[1]. Azithromycin specifically reduces MMP-9 mRNA and protein levels without affecting NF-κB in endotoxin-challenged monocytic THP-1 cells[2]. |
|---|
| In Vivo | Azithromycin (50 mg/kg) has no effect on bronchoalveolar lavage inflammatory parameters and LDH levels in a mouse model of asthma exacerbation. Azithromycin induces neither general inflammatory parameters nor LDH release in a mouse model of asthma exacerbation, and augments expression of interferon-stimulated genes and the pattern recognition receptor MDA5 but not RIG-I in exacerbating mice[1]. |
|---|
| Solvent | In Vitro: DMSO : ≥ 100 mg/mL (133.51 mM) H2O : < 0.1 mg/mL (insoluble) * "≥" means soluble, but saturation unknown. In Vivo: 1.Add each solvent one by one: 10% DMSO 90% corn oil Solubility: ≥ 2.5 mg/mL (3.34 mM); Clear solution 2.Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (3.34 mM); Clear solution 3.Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (3.34 mM); Suspended solution; Need ultrasonic |
|---|
| Solubility | 1 mM1.3351 mL6.6757 mL13.3515 mL5 mM0.2670 mL1.3351 mL2.6703 mL10 mM0.1335 mL0.6676 mL1.3351 mL |
|---|
China
